Adverum Biotechnologies, Inc.
ADVM
$3.43
$0.103.00%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.00M | 0.00 | 0.00 | 3.60M | 3.60M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.00M | 0.00 | 0.00 | 3.60M | 3.60M |
| Cost of Revenue | 68.22M | 68.53M | 72.03M | 77.68M | 82.91M |
| Gross Profit | -67.22M | -68.53M | -72.03M | -74.08M | -79.31M |
| SG&A Expenses | 35.65M | 39.66M | 48.34M | 49.69M | 47.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 103.88M | 108.18M | 120.37M | 127.37M | 130.56M |
| Operating Income | -102.88M | -108.18M | -120.37M | -123.77M | -126.96M |
| Income Before Tax | -95.24M | -100.98M | -113.99M | -118.24M | -126.11M |
| Income Tax Expenses | -1.13M | -1.12M | -1.10M | -1.08M | 74.00K |
| Earnings from Continuing Operations | -94.11 | -99.86 | -112.90 | -117.17 | -126.19 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -94.11M | -99.86M | -112.90M | -117.17M | -126.19M |
| EBIT | -102.88M | -108.18M | -120.37M | -123.77M | -126.96M |
| EBITDA | -99.02M | -103.71M | -115.32M | -118.12M | -120.61M |
| EPS Basic | -6.03 | -7.99 | -10.23 | -11.62 | -12.56 |
| Normalized Basic EPS | -3.83 | -5.05 | -6.45 | -7.32 | -7.54 |
| EPS Diluted | -6.03 | -7.99 | -10.23 | -11.62 | -12.56 |
| Normalized Diluted EPS | -3.83 | -5.05 | -6.45 | -7.32 | -7.54 |
| Average Basic Shares Outstanding | 68.33M | 57.55M | 46.78M | 40.33M | 40.20M |
| Average Diluted Shares Outstanding | 68.33M | 57.55M | 46.78M | 40.33M | 40.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
